NASDAQ:NERV Minerva Neurosciences (NERV) Stock Price, News & Analysis $1.49 +0.03 (+2.05%) Closing price 05/27/2025 03:58 PM EasternExtended Trading$1.50 +0.01 (+0.34%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Minerva Neurosciences Stock (NASDAQ:NERV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Minerva Neurosciences alerts:Sign Up Key Stats Today's Range$1.35▼$1.5050-Day Range$1.33▼$1.8752-Week Range$1.15▼$3.69Volume23,102 shsAverage Volume28,192 shsMarket Capitalization$10.42 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company OverviewMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Read More… Minerva Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreNERV MarketRank™: Minerva Neurosciences scored higher than 69% of companies evaluated by MarketBeat, and ranked 417th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMinerva Neurosciences has received no research coverage in the past 90 days.Read more about Minerva Neurosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Minerva Neurosciences are expected to decrease in the coming year, from ($0.30) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Minerva Neurosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.50% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 1.81%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.89 Percentage of Shares Shorted0.50% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 1.81%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.93 News SentimentMinerva Neurosciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Minerva Neurosciences this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.60% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by InstitutionsOnly 34.56% of the stock of Minerva Neurosciences is held by institutions.Read more about Minerva Neurosciences' insider trading history. Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NERV Stock News HeadlinesMinerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.comMay 21, 2025 | americanbankingnews.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | finanznachrichten.deAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.May 28, 2025 | Paradigm Press (Ad)Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 13, 2025 | globenewswire.comMinerva Neurosciences Inc.April 23, 2025 | barrons.comMinerva Neurosciences regains Nasdaq complianceMarch 21, 2025 | investing.comMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business UpdatesFebruary 25, 2025 | globenewswire.comMinerva Neurosciences stock hits 52-week low at $2.02February 12, 2025 | msn.comSee More Headlines NERV Stock Analysis - Frequently Asked Questions How have NERV shares performed this year? Minerva Neurosciences' stock was trading at $2.22 at the beginning of the year. Since then, NERV stock has decreased by 32.9% and is now trading at $1.49. View the best growth stocks for 2025 here. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc. (NASDAQ:NERV) announced its quarterly earnings data on Tuesday, May, 13th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.57. When did Minerva Neurosciences' stock split? Minerva Neurosciences's stock reverse split before market open on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. Who are Minerva Neurosciences' major shareholders? Minerva Neurosciences' top institutional investors include Apella Capital LLC (0.29%). Insiders that own company stock include Remy Luthringer, Geoff Race and Frederick W Ahlholm. View institutional ownership trends. How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Neurosciences investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), NIO (NIO), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO) and VBI Vaccines (VBIV). Company Calendar Last Earnings5/13/2025Today5/27/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NERV CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year Founded2007Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+235.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.82 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-6.74% Debt Debt-to-Equity RatioN/A Current Ratio6.23 Quick Ratio6.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.07) per share Price / Book-0.37Miscellaneous Outstanding Shares6,993,000Free Float6,392,000Market Cap$10.42 million OptionableNot Optionable Beta-0.50 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:NERV) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.